The invention provides proteins from Neisseria meningitidis , including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
1. A purified polypeptide comprising: (a) a fragment of an amino acid sequence of SEQ ID NO: 2534, wherein the fragment comprises 18 or more consecutive amino acids from the amino acid sequence, or (b) an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2534.
2. The purified polypeptide of claim 1 comprising the fragment, wherein the fragment comprises 20 or more consecutive amino acids from the amino acid sequence of SEQ ID NO: 2534.
3. The purified polypeptide of claim 1 comprising (b), wherein the amino acid sequence has at least 90% sequence identity to SEQ ID NO: 2534.
4. The purified polypeptide of claim 3 , in combination with a pharmaceutically acceptable carrier.
5. The purified polypeptide of claim 2 , in further combination with an adjuvant.
6. The purified polypeptide of claim 2 , in further combination with a pH buffering agent.
7. The purified polypeptide of claim 2 , wherein the fragment is an immunogenic fragment of SEQ ID NO: 2534.